HDM BIO, a cGMP-compliant peptide API manufacturer based in China, today announced the official scale-up of its commercial tirzepatide API production line to meet surging global demand for research-grade and bulk peptide raw materials. The newly expanded capacity delivers consistent batches of lyophilized tirzepatide peptide powder with a minimum purity of ≥98%, complete traceable quality documentation, and scalable supply volumes for pharmaceutical R&D laboratories, biotech firms and peptide distributors worldwide.
As shown above, HDM BIO's tirzepatide API is supplied as a sterile white lyophilized powder, available in both sealed glass vial samples and bulk aluminum foil packaging. Each unit is clearly labeled with exact batch number, manufacturing date, expiration date, and required storage condition of -20°C to preserve peptide activity during storage and transit. All production operations are conducted in ISO 9001 certified clean workshops under strict cGMP protocols, ensuring uniform physical properties and stable bioactivity across every production batch. The product is designated For Research Use Only, suitable for preclinical study, formulation development and raw material supply applications.
Why HDM BIO Stands Out as a Reliable Tirzepatide API Supplier
In the global tirzepatide raw material market, buyers frequently face three major supply risks: inconsistent purity across batches, missing or incomplete COA test reports, and unstable delivery lead times for bulk orders. HDM BIO addresses all these pain points through standardized GMP manufacturing management and full-process quality control systems.
The comparison chart above outlines the core differences between high-risk traders and professional GMP manufacturers across three critical dimensions. For quality control, HDM BIO guarantees stable ≥98% HPLC purity for every batch instead of fluctuating purity levels from unregulated suppliers. On documentation, we provide full traceable quality files including official COA, HPLC chromatograms and mass spectrometry reports for each shipment, eliminating the risk of missing certification documents. For supply capacity, our scalable GMP production lines support both small-batch R&D orders and large-scale commercial supply, with reliable lead times even for peak demand periods.
Tirzepatide API: Molecular Structure, Synthesis Technology and GMP Manufacturing
As a first-in-class dual GIP/GLP-1 receptor agonist peptide API, tirzepatide's biological performance and stability depend heavily on its precise molecular structure and controlled synthesis process. HDM BIO combines advanced SPPS synthesis technology, optimized purification workflows and GMP-grade production management to deliver high-quality tirzepatide raw material with consistent structural accuracy.
This overview covers three core technical pillars of HDM BIO's tirzepatide API: accurate molecular structure design, standardized SPPS synthesis process, and cGMP-compliant commercial production. Every production step follows validated SOPs to ensure the final peptide product matches the expected molecular profile and purity specifications.
Detailed Molecular Structure of Tirzepatide Peptide
Tirzepatide is a 39-amino-acid linear peptide engineered as a dual agonist for both GIP and GLP-1 receptors. Its unique structural design is the foundation of its biological activity and extended half-life in circulation.
As illustrated in the structural diagram, the tirzepatide peptide backbone contains two independent receptor binding regions: the N-terminal GIP receptor binding site and the GLP-1 receptor binding domain, enabling simultaneous activation of both metabolic regulatory pathways. A C20 fatty diacid side chain is attached at the Lys26 position via lipidation modification, which enhances albumin binding in vivo and significantly prolongs the circulation half-life of the peptide. This optimized structural design is strictly replicated in HDM BIO's synthesis process to ensure full retention of the peptide's intended biological properties.
6-Step SPPS Synthesis & Purification Process for Tirzepatide API
HDM BIO adopts mature solid-phase peptide synthesis (SPPS) technology to manufacture tirzepatide API, with a fully validated 6-step production workflow that ensures high purity, low impurities and batch-to-batch consistency.
The standardized production process proceeds as follows:
- Resin Loading: The first C-terminal amino acid is anchored to a solid resin support to initiate the synthesis cycle.
- Peptide Chain Elongation: Protected amino acids are sequentially coupled to the growing peptide chain through repeated Fmoc deprotection and coupling cycles.
- Side Chain Modification: The lipidated fatty acid moiety is introduced at the specific Lys26 site to achieve the required albumin-binding property.
- Cleavage: The fully assembled peptide chain is cleaved from the resin support under acidic conditions, with simultaneous removal of side-chain protecting groups.
- HPLC Purification: Reverse-phase high-performance liquid chromatography is applied to remove impurities, achieving a final purity of ≥98% for all finished batches.
- Lyophilization: The purified peptide solution is freeze-dried into stable white lyophilized powder for long-term storage and convenient transportation.
All batches undergo full quality inspection including HPLC purity testing, mass spectrometry identification and moisture content analysis before release. The entire production system complies with GMP standards, delivering low impurity profiles and highly consistent quality from batch to batch.
Supply, Packaging and Global Delivery Services
HDM BIO offers flexible supply options for tirzepatide API, ranging from milligram-level research samples to kilogram-level bulk commercial orders. All bulk shipments are packaged in food-grade aluminum foil bags with sealed inner vials, and global cold chain logistics solutions are available to maintain low-temperature storage conditions during international transit.
We provide complete supporting documents for every order, including official Certificate of Analysis (COA), material safety data sheet and batch traceability records. Custom synthesis specifications and packaging options are also available upon request to meet specific project requirements.
To request a full COA report, inquire about bulk tirzepatide API pricing, or schedule a virtual factory audit, please contact our technical sales team at sales@hdmbio.com. HDM BIO is committed to being your long-term reliable partner for high-quality peptide API supply.